比较低剂量率或高剂量率前列腺近距离放疗推量联合盆腔外照射放疗后生活质量的随机试验
该随机试验纳入195例中危或高危前列腺癌患者,比较盆腔外照射放疗联合高剂量率(15 Gy)或低剂量率(110 Gy)近距离放疗推量后的泌尿、肠道和性功能生活质量。高剂量率组泌尿生活质量1个月下降但6个月恢复稳定,低剂量率组3个月达最低点并缓慢恢复至18个月,此后两组泌尿生活质量相似;两组肠道生活质量均下降并于12个月达最低点,高剂量率组恢复接近基线并维持更高评分至5年,低剂量率组下降超过最小临床重要差异并持续至5年。
要点
- 高剂量率组泌尿生活质量1个月下降但6个月恢复稳定,低剂量率组3个月达最低点并缓慢恢复至18个月。
- 18个月后两组泌尿生活质量相似,但低剂量率组报告持续肠道症状至5年。
- 高剂量率组肠道生活质量恢复接近基线并维持更高评分至5年,低剂量率组下降超过最小临床重要差异至5年。
核心结论
- 盆腔外照射放疗联合前列腺近距离放疗的患者体验在高剂量率近距离放疗下得到改善。
- 泌尿生活质量随时间改善,18个月后两种模式等效,但低剂量率患者报告持续肠道症状。
研究设计与样本
- 随机试验于2014年1月至2019年12月纳入195例接受盆腔外照射放疗联合近距离放疗的中危或高危前列腺癌男性,随机分为高剂量率组(15 Gy,108例)和低剂量率组(110 Gy,87例)。
- 中位年龄71岁,高危占57%,不利中危占43%,74%使用雄激素剥夺治疗(开始为3个月新辅助,中位持续12个月)。
- 在基线、1、3、6、12个月、每6个月至3年、之后每年收集国际前列腺症状评分、勃起功能指数和扩展前列腺癌复合指数,并检测前列腺特异性抗原/睾酮。
- 分类变量采用Fisher精确检验,扩展前列腺癌复合指数(EPIC)域评分采用Mann-Whitney U检验。
主要发现
- 基线EPIC评分在低剂量率/高剂量率组相似:泌尿领域分别为89和88,肠道领域分别为92和93。
- EPIC泌尿评分在高剂量率组1个月下降但6个月迅速恢复至稳定状态;低剂量率组3个月达最低点并缓慢恢复至18个月,此后两组泌尿生活质量相似。
- 两组肠道生活质量评分均下降,分别在12个月达最低点;高剂量率组恢复接近基线并维持更高评分至5年。
- 低剂量率组肠道评分下降超过最小临床重要差异并持续至5年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare health-related quality of life (QoL) in urinary, bowel, and sexual domains after combined external beam radiation therapy (EBRT) and either low-dose rate (LDR) or high-dose rate (HDR) prostate brachytherapy (BT). METHODS AND MATERIALS: Eligible men with intermediate or high-risk prostate cancer treated with combined pelvic EBRT and BT were randomly assigned to either HDR (15 Gy) or LDR (110 Gy) boost. International Prostate Symptom Score, Index of Erectile Function, and Expanded Prostate Cancer Composite were collected at baseline, 1, 3, 6, and 12 months, every 6 months to 3 years and then annually along with prostate-specific antigen/testosterone. Fisher's exact test compared categorical variables and the Mann-Whitney U test Expanded Prostate Cancer Index Composite (EPIC) domain scores. RESULTS: From January 2014 to December 2019, a random number generator assigned 195 men: 108 to HDR and 87 to LDR. Median age was 71 years. Risk group was high in 57% and unfavorable intermediate in 43%. Androgen deprivation (used in 74%) began with 3 months neoadjuvant and continued for median 12 months. Baseline EPIC scores were similar for the LDR/HDR cohorts: 89 and 88 respectively for Genito-urinary; 92 and 93 for Gastro-intestinal. EPIC urinary scores decreased at 1 month for HDR but recovered promptly to a steady state by 6 months. LDR scores reached a nadir at 3 months with slow recovery to 18 months, after which urinary QoL was similar for HDR and LDR. Bowel QOL scores fell in both cohorts reaching respective nadirs at 12 months. HDR patients recovered close to baseline and maintained higher scores than LDR patients to 5 years. The decline for LDR patients remained more than the minimum clinically important difference out to 5 years. CONCLUSIONS: The patient experience for combined EBRT and prostate BT is improved with HDR BT. Urinary QoL improves over time to be equivalent between the 2 modalities after 18 months, but LDR patients report lasting bowel symptoms.
引用
- Crook J, Moideen N, Arbour G, et al. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38493901. doi:10.1016/j.ijrobp.2024.02.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。